Tag: non-small cell lung cancer
-

Roche’s Divarasib Improves Survival in Phase 3 KRAS G12C Lung Cancer Trial
Roche’s divarasib improved median overall survival to 17.7 months versus 12.0 months with sotorasib or adagrasib in Phase 3 Krascendo 1. The findings inform treatment choice in KRAS G12C-mutated lung cancer but do not establish efficacy after KRAS-inhibitor resistance.
-

Bayer’s Hyrnuo Wins First-Line FDA Approval in HER2-Mutant Lung Cancer
The FDA granted Bayer’s Hyrnuo accelerated approval as a first-line treatment for HER2-mutant non-small cell lung cancer after the oral therapy achieved a 75% response rate in SOHO-01.